AIMC Topic: Phosphodiesterase 4 Inhibitors

Clear Filters Showing 1 to 2 of 2 articles

Probing the dark chemical matter against PDE4 for the management of psoriasis using in silico, in vitro and in vivo approach.

Molecular diversity Mar 17, 2025
The potential downsides for the present treatment for psoriasis are drug resistance, reduced efficacy, risk of mental episodes, and drug interactions. Hence, this study aims to discover a new drug for psoriasis by considering global research efforts ...
Humans Animals Molecular Docking Simulation Drug Discovery Mice Psoriasis Molecular Dynamics Simulation Ligands Phosphodiesterase 4 Inhibitors Cyclic Nucleotide Phosphodiesterases, Type 4
View on PubMed DOI

[Optimization and evaluation of an inflammatory cell model in LPS-stimulated PMA-differentiated THP-1 cells].

Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology Nov 1, 2017
Objective To develop an optimal inflammatory cell model from lipopolysaccharide (LPS)-stimulated phorbol ester (PMA)-differentiated THP-1 cells, and investigate its response to anti-inflammatory agent phosphodiesterase inhibitor rolipram. Methods THP...
Humans Tumor Necrosis Factor-alpha Macrophages Interleukin-6 Lipopolysaccharides Cell Differentiation Anti-Inflammatory Agents Models, Biological THP-1 Cells Inflammation Mediators Tetradecanoylphorbol Acetate Leukemia, Monocytic, Acute Phosphodiesterase 4 Inhibitors Rolipram
View on PubMed
Popular Topics
Recent Journals